Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 8/20 | 1.00 |
| ▸ | BCHE | P06276 | 8/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Donepezil SCHEMBL2149 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3851203 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL8265876 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL12043710 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL4979379 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL356844 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1559622 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1815 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL17352708 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL5060933 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12533 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680633-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | Alzpath, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-20260008840-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | ALZPATH INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250333435-A1 | TIMOSAPONIN COMPOUNDS | GOLDPORP PHARMA LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250304565-A1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix Inc. (US) | 2025-10-02 | — | — | US | claimed |
| EP-3562483-B1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250134959-A1 | GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR NEURODEGENERATIVE OR NEUROLOGICAL DISEASES OR DISORDERS | PARTNER THERAPEUTICS, INC. | 2025-05-01 | — | — | US | claimed |
| US-12234258-B2 | Timosaponin compounds | GOLDPORP PHARMA LIMITED (CN) | 2025-02-25 | — | — | US | claimed |
| CN-119522282-A | Splice transducer antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-25 | — | — | CN | claimed |
| US-20250059584-A1 | METHODS FOR DIAGNOSING AND/OR TREATING ALZHEIMER'S DISEASE | SEQ BIOMARQUE, LLC | 2025-02-20 | — | — | US | claimed |
| WO-2002032412-A2 | COMBINATION USE OF ACETYLCHOLINESTERASE INHIBITORS AND GABAA INVERSE AGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| WO-2002024652-A1 | COMPOUNDS AND METHODS FOR DIAGNOSING AND TREATING AMYLOID-RELATED CONDITIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| US-20020028826-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-07 | — | — | US | claimed |
| US-20020013334-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | claimed |
| WO-2001096347-A1 | HMG-CoA REDUCTASE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001096311-A2 | HMG-COA REDUCTASE INHIBITORS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF CHOLESTEROL RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001085145-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNCTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| EP-1124555-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| WO-2000012093-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | claimed |